This current study tested expression and potential biological functions of Gab3 in human glioma. Gab3 mRNA and protein expression was significantly elevated in human glioma tissues and glioma cells. Its level was however low in normal brain tissues and primary human astrocytes. In both established (U251MG cell line) and primary human glioma cells, Gab3 knockdown by shRNA/siRNA significantly inhibited Akt activation and cell proliferation. Reversely, forced Gab3 overexpression in U251MG cells promoted Akt activation and cell proliferation. In vivo, the growth of U251MG tumors in nude mice was inhibited following expressing Gab3 shRNA. Akt activation in cancer tissues was also suppressed by Gab3 shRNA. Together, we conclude that Gab3 overexpression in human glioma mediates Akt activation and cancer cell proliferation.
Introduction
Glioma is a common cancer in the central nerves system (CNS), which causes significant human mortalities each year [1, 2, 3] . The prognosis of high-grade glioma (grade III-IV) is extremely poor [1, 2, 3] . The incidence of this devastating disease, however, has been rising in certain areas [1, 2, 3] . The application of current clinical treatments, including postoperative radiation and/or adjuvant temozolomide, failed to significantly improve patents' five-year survival [4, 5, 6] . One possible factor could be the molecular heterogeneity of glioma [1] . Therefore, our group has been dedicated to indentify novel oncogenic proteins for human glioma [7, 8, 9, 10, 11] .
The mammalian Gab [growth factor receptor binding 2 (Grb2)-associated binding protein] family of proteins have three members, Gab1, Gab2 and Gab3 [12, 13] . The adaptor protein Gab3, like other Gab proteins, could be tyrosine phosphorylated [14, 15, 16] . Gab3 associates with the SH2 domain-containing proteins, i.e. PI3K regulatory subunit p85 [14, 15, 16] . This presumably will mediate Akt signaling activation [14, 15, 16] . Existing evidence has demonstrated that Gab3 is more restricted to the hematopoietic tissues (i.e. spleen and thymus) [14, 15, 16] . Yet, its expression is also detected in other tissues, including heart, kidney, uterus, and brain [14, 15, 16] . A very recent study has explored expression of Gab1 in human glioma a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
Cell death detection
Cells with applied treatment were harvested, washed and stained with trypan blue dye (Sigma). Cells with compromised cell membranes took up trypan blue, and were counted as dead cells [8, 9] .
BrdU assay of proliferation
Cells with the designated treatment were incubated with BrdU (5 μM) and were fixed. BrdU incorporation, deterring cell proliferation, was tested by the BrdU ELISA kit (Roche Diagnostics).
Clonogenicity assay
As described, [8, 9, 18] , U251MG cells with applied genetic modification (5 × 10 3 per dish) were resuspended in agar-containing medium, and were cultured on a 100 mm culture dish. After 10 days of culture, the proliferative colonies were manually counted.
Apoptosis analysis
As described early [9] ,cells with applied treatment were washed. Afterwards, propidium iodide (50 μg/mL), Annexin V-FITC (50μg/mL) and 0.1% Triton X-100 were added [8] . Annexin V positive cells (apoptotic cells) were gated by FACS machine (FACS Canto II flow cytometer, Shanghai, China).
Quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR assay)
RNA was extracted via the routine Trizol reagents (Invitrogen). For each preparation, 1 μg RNA, 100 nM primers and 1× SYBR Master Mix (Applied Biosystem, Shanghai, China) were mixed. The ABI Prism 7600 Fast Real-Time PCR system (Foster City, CA) was applied for real-time PCR reactions. Melt curve analysis was tested to analyze product melting temperature. Quantification of listed mRNA was through the ΔΔ Ct method. GAPDH was also tested as the internal control. The primers were as follows:Gab1: forward, 5'-GCATGGAAGAGGAGA TGGTTCGTGT-3' and reverse: 5'-AGTAGCAGAGGATGAATCTGCCTGG-3' [19] ; Gab3, forward: 5'-GAGAGCCTCTCTTACACG-3' and reverse: 5'-GGCTGAAGCTGTGGGGTA-3' [19] ; GAPDH, forward: 5'-TGAAGGTCGGAGTCAACGGATTTGG-3' and reverse: 5'-CAT GTGGGCCATGAGGTCCACCAC-3' [19] . The primers were purchased from Jikai (Suzhou, China).
Western blotting assay
As described [9] , equal amount of lysates (30 μg per sample) were separated by SDS-PAGE gels, and were transferred to PVDF membranes. After blocking, indicated primary antibody and secondary antibody were added. Enhanced chemiluminescence (ECL) reagents (Amersham, Shanghai, China) were applied to visualize the intend band. The densitometry of each band was quantified via the ImageJ software, and its value was always normalized to the corresponding loading control(unless otherwise noted) [9] .
Immunoprecipitation (IP)
The detailed protocol was described in other studies [20, 21] . Briefly, aliquots of 800 μg of protein lysates from each sample were pre-cleared by protein A/G beads (Sigma), followed by incubation with anti-Gab3 antibody overnight. Thirty μl of protein A/G beads (Sigma) were then added, and the lysates were incubated for 2 hours at 4˚C. The beads were washed with PBS for 5 times. Afterwards, Gab3-assocaited proteins were detected by Western blotting assay.
Gab3 knockdown by shRNA and stable cell selection
The three different lentiviral Gab3short hairpin RNAs ("shGab3-a/-b/-c", Catalog no. GP-2015-139716sh-a/-b-c) were designed by Jikai Biotech (Suzhou, China). The shRNA was added to cultured U251MG cells for 24 hours. Afterwards, puromycin (0.5 μg/mL, Sigma) was applied to select stable clones for 8-9 days. Control cells were incubated with lentiviral scramble non-sense shRNA (Santa Cruz) [9, 18] . Gab3 knockdown in stable cells was verified by Western blotting assay and/or qRT-PCR assay.
Gab3 RNA interference in primary cells
Two Gab3 siRNAs (Gab3 siRNA-a: from Santa Cruzsc-40608, Gab3 siRNA-b: from ABM, i008390) and a non-specific scramble siRNA ("si-SCR", Santa Cruz) were applied, and transfected into primary human glioma cells with Lipofectamine 2000 (Invitrogen). Knockdown efficiency was again determined by qRT-PCR andWestern blotting assay 48 hours after transfection.
Gab3 overexpression
The human Gab3 cDNA, synthesized by theJikai Biotech (Shanghai, China), was inserted into the GV428 expression vector, which contained a Flag tag and a puromycin resistance gene. U251MG cells were seeded onto six-well plates. Gab3 expression construct (0.25 μg/mL) was transfected to U251MG cells via the Lipofectamine 2000 reagents [22] , and stable cells were selected by the puromycin. Transfection efficiency was verified via testing Gab3 (Flag-tagged) expression in stable cells. , and the recordings were initiated. The tumor volumes and mice body weights were recorded every 6 days. Volumes were calculated via the formula: π/6×width 2 × length. Estimated average daily tumor growth was also calculated [22, 23] . The animal protocols were approved by Institutional Animal Care and Use Committee (IACUC) and ERB (approval number, BR-2014-188) of Shanghai Jiao-Tong University School of Medicine (Shanghai, China). Animals were observed on daily bases. Humane endpoints were defined as a loss of more that 15% of body mass, a tumor with the diameter over 1.3 cm, or inability to ambulate or rise for food and water. If reaching these endpoints, CO 2 inhalation was used for euthanasia of animals. All mouse surgical procedures were performed with anesthesia by injection of ketamin/xylazine HCl (50 mg/kg/10 mg/kg, i.p.). All efforts were made to minimize suffering.
Xenograft assay

Statistical analysis
Statistics were performed through the SPSS 18.0 software (Chicago, IL). For each set of in vitro cell line experiment, at least 5 replicate wells (n = 5) were included, mean ± standard deviation (SD) were calculated. Statistics was then performed. Afterwards, the whole set of experiment was repeated 3-5 times, making sure similar results were reproduced. p<0.05 was considered statistically significant.
Results
Gab3 overexpression in both human glioma tissues and glioma cells
We first tested expression of Gab3 in human glioma tissues. As discussed, a total of seven different high-grade glioma tissues ("Tumor") and the paired surrounding normal brain tissues ("Normal") were acquired. qRT-PCR assay results demonstrated that Gab3 mRNA expression in the tumor tissues was significantly higher than that in the normal brain tissues (Fig 1A) . Gab3 mRNA level was about four times higher in tumor tissues ( Fig 1A) . Further analysis showed that Gab3 protein expression was also upregulated in the tumor tissues (See representative blots of two patients in Fig 1B, Left panel) . Its expression in normal brain tissues was low ( Fig 1B) . The quantified blot results of all seven sets of tissues were integrated (Fig 1B, right panel).Gab3 expression in cultured human glioma cells was also tested. In both established (U251MG cell line) and primary human glioma cells ("Glioma cells"),Gab3 mRNA ( Fig 1C) and protein( Fig 1D) expression level was significantly higher than that in the primary human astrocytes ("Astrocytes"). Thus, these results demonstrate Gab3 overexpression in both human glioma tissues and glioma cells. Expressions of two other adaptor proteins, including p85 and SHP2, were also upregulated in the glioma cells ( Fig 1D) . Next, the immunoprecipitation (IP) assay was performed to examine the association between Gab3 and other proposed adaptor proteins. Results in Fig 1E showed that there was a strong association between Gab3 and p85 in both U251MG cells and primary human glioma cells. Gab3-p85 association was not observed in the primary astrocytes (Fig 1E) . Interestingly, Gab3 didn't form a complex with SHP2 in above glioma cells (Fig 1E) . These results imply that Gab3 possibly serves as the upstream of p85-Akt signaling in glioma cells.
Gab3 knockdown by shRNA inhibits U251MG glioma cell proliferation
In order to study the potential effect of Gab3 on human glioma cells in vitro, shRNA strategy was applied. As discussed, a set of three distinct Gab3 shRNAs ("shGab3-a/-b/-c") with nonoverlapping sequences were introduced to U251MG glioma cells. Puromycin was added afterwards to select stable cells. qRT-PCR assay results in Fig 2A demonstrated that each of the three applied Gab3 shRNAs dramatically downregulated Gab3 mRNA expression in U251MG cells. Gab1 mRNA expression was unchanged (Fig 2A) . Western blotting assay results in Fig  2B confirmed Gab3 protein knockdownin above U251MG cells. Once again, Gab1 protein expression was not changed (Fig 2B) . Remarkably, the proliferation of U251MG cells, tested by MTT assay (Fig 2C) and BrdU ELISA assay (Fig 2D) , was inhibited significantly with Gab3 knockdown. The MTT OD and BrdU ELISA OD were both decreased in cells with Gab3 shRNAs, as compared to those of parental control ("Ctrl") cells (Fig 2C and 2D) . Meanwhile, the number of proliferative U251MG colonies was also decreased with Gab3 shRNA (Fig 2E) . Intriguingly, U251MG cell death (tested by trypan blue staining assay) and apoptosis (tested by the Annexin V FACS assay) were not significantly altered after Gab3 knockdown (Fig 2F) . There results suggest that Gab3 knockdown inhibits U251MG glioma cell proliferation. As expected, the scramble control shRNA ("sh-SCR") didn't affect Gab1/3 expression (Fig 2A and  2B ) and U251MG cell proliferation (Fig 2C-2F ).
Gab3 siRNA inhibits primary human glioma cell proliferation
Next, we tested the potential effect of Gab3 on primary cancer cells. As discussed, one primary human glioma cell line was established. siRNA strategy was utilized to transiently knockdown Gab3 in the primary cells. As shown in Fig 3A, transfection of two applied Gab3 siRNAs ("siGab3-a/-b") efficiently downregulated Gab3 mRNA (but not Gab1) in the primary glioma cells. Further, Gab3 protein expression was also decreased (Fig 3B) . Significantly, MTT assay results in Fig 3C and BrdU ELISA results in Fig 3D demonstrated that Gab3 siRNA similarly inhibited proliferation of the primary human glioma cells. Notably, siGab3-b was more efficient in downregulating Gab3 than siGab3-a (Fig 3A and 3B) , it was also more potent in inhibiting cell proliferation (Fig 3C and 3D) . We failed to detect significant cell death and apoptosis following Gab3 knockdown in the primary cancer cells (Fig 3E) . The scramble control siRNA ("si-SCR") didn't affect Gab3 expression (Fig 3A and 3B ) and cancer cell proliferation (Fig 3C  and 3D) . Thus, knockdown of Gab3 inhibits proliferation of the primary human glioma cells. Similar results were also obtained from other replicate primary glioma cell lines (Data not shown).
Forced overexpression of Gab3 promotes U251MG glioma cell proliferation
Next, a Gab3 expression construct was established, which was transfected to U251MG cells. Via puromycin selection, two stable U251MG cell lines-overexpressing Gab3 (Flag-tagged) were established, named "Gab3-L1/L2". As compared to parental control ("Ctrl") cells, mRNA ( Fig 4A) and protein (Fig 4B) expression of Gab3 was significantly upregulated in U251MG cells with the construct. Gab1 expression was again unchanged in these cells (Fig 4A) . Importantly, U251MG cell proliferation, tested by MTT assay (Fig 4C) and BrdU ELISA assay ( Fig  4D) , was augmented in Gab3-overexpressed cells ("Gab3-L1/L2"). Expectably, the empty vector ("Vector", pSuper-puro) failed to affect Gab3 expression (Fig 4A and 4B ) and U251MG cell proliferation (Fig 4C and 4D) . Therefore, these results suggest that forced expression of Gab3 promotes U251MG glioma cell proliferation, further confirming a role of Gab3 in promoting glioma cell proliferation.
Gab3 is important for Akt activation in human glioma cells
Existing evidences have demonstrated that Akt signaling plays a pivotal role in promoting glioma cell progression [24, 25, 26] . Activation of Akt in glioma cells participates in a number of key cancerous behaviors, including cell proliferation, migration and motility, survival, angiogenesis and apoptosis resistance [24, 25, 26] . We thus tested Akt activation in above glioma cells. As shown in Fig 5A, Gab3 known by targeted-shRNA in U251MG cells dramatically inhibited Akt activation, the latter was tested by phosphorylation (p-) of Akt at Thr-308. p-Akt level was reduced in all three U251MG cell lines expressing Gab3 shRNA (Fig 5A) . In the primary human glioma cells, siRNA-mediated knockdown of Gab3 also inhibited Akt activation (Fig 5B) . On the other hand, as shown in Fig 5C, forced overexpression of Gab3 in U251MG cells augmented Akt activation. Gab3 overexpression failed to affect Erk1/2 activation (pErk1/2) in U251MG cells (Fig 5C) . These results suggest that Gab3is important for Akt activation in human glioma cells.
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E. In order to confirm the role of Akt activation in Gab3-promoted cell proliferation, Akt inhibitors were applied, including the pan PI3K-Akt inhibitor LY294002 [27] and the Akt specific inhibitor perifosine [28] . Expectably, application of both inhibitors suppressed U251MG cell proliferation, which was again tested by the MTT assay (Fig 5D) and BrdU ELISA assay (Fig 5E) . More importantly, Gab3 overexpression-promoted U251MG cell proliferation was almost completely blocked with treatment of the PI3K-Akt inhibitors (Fig 5D and 5E) . These results suggest that Gab3 overexpression-induced glioma cell proliferation likely is mediated through activating downstream Akt.
Gab3 knockdown suppresses U251MG xenograft tumor growth in nude mice
In order to test the potential effect of Gab3 on glioma cell proliferation in vivo. A nude mice U251MG xenograft model was applied. As described, same amount of U251MG cells expressing scramble control shRNA ("sh-SCR") or Gab3 shRNA (shGab3-c) were inoculated. Fig 6A  recorded tumor volumes, and results showed that the growth of U251MG tumors with Gab3 shRNA was much slower than those with scramble control shRNA (Fig 6A) . The volume of tumors expressing Gab3 shRNA was significantly lower than the control shRNA tumors ( Fig  6A) . When calculating daily tumor growth (in mm 3 per day), we showed again that growth of U251MG tumor in vivo was dramatically suppressed following expressing Gab3 shRNA ( Fig  6B) . At Day-13 and Day-25, one U251MG tumor per group was isolated. Western blotting assay of tumor lysates showed that Gab3 was indeed depleted in Gab3 shRNA-expressing tumors (Fig 6C) . Meanwhile, Akt activation, tested by p-Akt (Thr-308), was also reduced in the tumors (Fig 6C) . Therefore, in line with the in vitro signaling findings, Gab3 knockdown also inhibited Akt activation in vivo. Results in Fig 6D demonstrated 
Discussion
In various cell types, Gab family members, including Gab1, Gab2 and Gab3, play crucial roles in mediating multiple signaling pathways, which are important for cell proliferation, survival, and differentiation [12, 13, 29] . Upon activation, Gab proteins are tyrosine phosphorylated, which then bind to SHP2, the PI3K subunit p85, as well as Crk family proteins. This would lead to activation of MAPK, PI3K-Akt, and JNK [12, 13, 29] , which are all vital oncogenic pathways. Recent studies have focused on the potential function of Gab family proteins in tumorigenesis, cancer differentiation and progression [12] . To data, Gab1 is the most predominant Gab family member protein, which is ubiquitously expressed in almost all mammalian cells and tissues [12] . Studies have implied Gab1 as a oncogenic protein in multiple human cancers, whose overexpression is associated with cancer cell progression [12] . A very recent study has suggested that Gab1 is important for activation of PI3K-Akt-mTOR activation in human glioma cells [17] . On the other hand, Gab3 is the least ubiquitously expressed member of the Gab family protein, and it is predominantly expressed in hematopoietic cells [14, 15, 16] . In the brain, yet weak Gab3 expression was still detected [14, 15, 16] . To our best knowledge, the expression and potential function of Gab3 in human cancer has not been studied thus far.
It should be noted that exogenous Gab3 overexpression only increased glioma cell proliferation by 20-30% (Fig 4) . This could be due to the fact that basal Gab3 expression is already high in glioma cells (Fig 1) . It is also possible that other Gab proteins, including Gab1 and Gab2, could also be required for cell proliferation as well. Indeed, the recent paper by Li et al., has implied a role of Gab1 in glioma cell proliferation [17] . Further studies will be need to dissect the role of each Gab protein in mediating Akt activation and glioma cell proliferation. One other reason could be that Gab3 appears not required for Erk activation in glioma cells. Gab3 didn't form a complex with SHP2 in the glioma cells. Further, exogenous Gab3 overexpression failed to affect Erk1/2 activation (p-Erk1/2) in U251MG cells.
The preclinical results of our study suggest that Gab3 should be a novel oncogenic protein for human glioma. First, Gab3 mRNA and protein expression was significantly elevated in both human glioma tissues and glioma cells, yet its level was quite low in normal brain tissues and human astrocytes. Second, glioma cell growth was inhibited by Gab3 knockdown, but was augmented with Gab3 overexpression. Third, in human glioma cells, Gab3 is required for the activation of Akt, which is key oncogenic pathway in glioma [30, 31] . Importantly, growth of U251MG tumor in vivo was remarkably inhibited when expressing Gab3 shRNA. Therefore, Gab3 could be a novel oncotarget protein for glioma.
Conclusion
Even with the development of modern clinical practice, the prognosis of high-grade glioma is still extremely poor, and the five-year survival is rare [3] . Late diagnosis, absence of specific markers, resistance of traditional therapy, as well as high invasion potential are all possible causes of its high-malignant nature [6, 25] . Our results showing that Gab3 overexpression in human glioma mediates Akt activation and cancer cell proliferation suggest that Gab3 could be a novel oncogenic protein for glioma.
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